The new COVID-19 booster shots are prized for their ability to recognize the distinctive spike protein shared by BA.4 and BA.5. But sooner or later, mutations in the spike protein will allow the virus to slip past the antibodies that are trained to recognize its predecessors. An experimental vaccine aims to solve that problem by priming the immune system to recognize a second — and far more stable — viral protein. When tested in small animals, this bivalent vaccine provided stronger protection than alternatives that targeted only one of the proteins.Read Long Article
